. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012 Nov;69(11):1445-52. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ1-42
(CSF)
AD
(48)
385 ± 97
ng/mL §
xMAP;
Other/Not Specified;
In-house
McKhann et al., 1984
Aβ1-42
(CSF)
CTRL-
CNC
(107)
616 ± 157
ng/mL §
xMAP;
Other/Not Specified;
In-house
NFL
(CSF)
AD
(48)
2569 ± 1814
ng/mL §
ELISA;
Other/Not Specified;
UmanDiagnostics AB
McKhann et al., 1984
NFL
(CSF)
CTRL-
CNC
(107)
1140 ± 1210
ng/mL §
ELISA;
Other/Not Specified;
UmanDiagnostics AB
tau-p181
(CSF)
AD
(48)
100 ± 37
ng/mL §
xMAP;
Other/Not Specified;
In-house
McKhann et al., 1984
tau-p181
(CSF)
CTRL-
CNC
(107)
54 ± 15
ng/mL §
xMAP;
Other/Not Specified;
In-house
tau-total
(CSF)
AD
(48)
944 ± 502
ng/mL §
xMAP;
Other/Not Specified;
In-house
McKhann et al., 1984
tau-total
(CSF)
CTRL-
CNC
(107)
569 ± 356
ng/mL §
xMAP;
Other/Not Specified;
In-house

§ Data supplied to Alzforum by author

Recommends

Please login to recommend the paper.

Comments

Make a Comment

Comments on this Paper

  1. This new report from Kaj Blennow and Oskar Hansson's group appears to support our own findings that soluble α-synuclein levels are increased in brains of subjects with AD (Larson et al., 2012). Whether this elevation corresponds to a "leakage of α-synuclein from degenerating neurons" or to an influx of α-synuclein in the CSF from the periphery remains to be demonstrated. We would favor an alternate hypothesis, i.e., that brain expression of α-synuclein is profoundly increased in AD, resulting in enhanced secretion of the protein into the interstitial fluid (ISF). Another key question relates to the nature of the soluble species of α-synuclein accumulating in AD, whether it is in the ISF, CSF, or neuronal cells. More work is needed to address this question at this time. Overall, this new study and ours highlight the possible involvement of soluble α-synuclein as an important modulator of AD pathophysiology.

    References:

    . Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci. 2012 Jul 25;32(30):10253-66. PubMed.

Make a Comment

To make a comment you must login or register.